

## Modern Slavery Statement

Throughout this statement, 'modern slavery' refers to all forms of forced labour, child labour, and human trafficking.

15<sup>th</sup> June 2026

### Introduction from the Chief Financial Officer

Modern slavery remains a global issue. At Quotient Sciences, we are committed to ethical and transparent employment practices, which are central to our corporate values.

The Modern Slavery Act 2015 provides an important framework through which we formalise and communicate our approach to preventing modern slavery and human trafficking within our business and supply chain.

Quotient Sciences takes a risk-based and proportionate approach to preventing modern slavery and human trafficking. We seek to work with suppliers and subcontractors who share our values and to put in place appropriate policies, procedures and controls designed to identify, assess and mitigate the risk of modern slavery within our operations and supply chains.

### Organisation's Structure

Quotient Sciences provides early-phase clinical research, drug manufacturing, formulation development, and data analysis services in the pharmaceutical sector, headquartered in the UK and with a UK annual turnover exceeding £36 million.

Globally we have over 1,000 employees, operating in Europe and North America.

### Our Supply Chains

Our supply chains include providers of:

- Clinical trials and drug manufacturing equipment.
- Specialised industry-specific equipment and technologies.
- Clinical trial-specific human sample analysis.

Our supply chains are predominantly business-to-business and operate mainly within regulated pharmaceutical and life sciences markets. We recognise, however, that modern slavery risks can arise at different tiers of supply chains and may vary depending on geography, sector and labour intensity.

## Our Policies on Modern Slavery

We are committed to acting ethically and with integrity in all our business relationships and to implementing effective systems and controls designed to prevent modern slavery, child labour and human trafficking in our business and supply chains.

We have a Child and Forced Labor Prevention Policy in place, which sets out our expectations regarding fair employment practices and compliance with applicable laws and standards.

## Due Diligence Processes

To mitigate the risk of involuntary labour, we have systems to:

- Identify and assess potential risk areas in our supply chains.
- Mitigate the risk of slavery and human trafficking.
- Monitor potential risk areas.
- Enable colleagues to report concerns via a whistleblowing mechanism.

Our due diligence activities are informed by the nature of our operations, the profile of our suppliers and the jurisdictions in which they operate. Where appropriate, we seek to integrate modern slavery considerations into procurement and supplier management processes.

## Supplier Adherence to Our Values

Quotient Sciences has zero tolerance for modern slavery. We expect all suppliers to comply with our values and promote transparency. Our Supplier Code of Ethics and Conduct, established in 2021, mandates adherence to high business ethics standards, including zero tolerance for modern slavery, freely chosen employment, and no child labour. This is supported by our Sustainable Procurement Policy.

Copies of both documents can be found on our website: [Suppliers \(quotientsciences.com\)](https://www.quotientsciences.com/suppliers).

## Our Effectiveness in Combating Slavery and Human Trafficking

We measure our effectiveness through key performance indicators:

- Validation of all suppliers against Quotient Sciences' quality management system.
- Auditing and profiling key suppliers as required.

- Use of a sophisticated payroll system.
- Monitoring the number of whistleblower cases on forced labour (zero for 2021, 2022, 2023, 2024 and 2025).

### Training and Awareness

We provide training and guidance to relevant colleagues to support awareness of modern slavery risks and to reinforce expectations relating to ethical employment practices, procurement and supplier engagement. Training content and delivery are kept under review to ensure they remain appropriate to risk and role.

### Approval

This statement is made pursuant to section 54(1) of the Modern Slavery Act 2015 and constitutes our slavery and human trafficking statement for the financial year ending 31 December 2025.

This statement has been approved by the Board of Directors of Quotient Sciences Limited.



Des Glass  
Chief Financial Officer  
Quotient Sciences Limited